Skip to main content
. 2016 Oct 31;76(4):694–700. doi: 10.1136/annrheumdis-2016-209821

Table 1.

Patient-reported outcomes at week 12 and week 24

Patient-reported outcome measure (least-squares mean (95% CI) from baseline at week 12 or 24, unless specified otherwise) Week 12
Week 24
Placebo
(N=176)
Baricitinib 2 mg
(N=174)
Baricitinib 4 mg
(N=177)
Placebo
(N=176)
Baricitinib 2 mg
(N=174)
Baricitinib 4 mg
(N=177)
EQ-5D-5L
Health State Index Score
 UK algorithm 0.036 (−0.000 to 0.073) 0.114*** (0.077 to 0.150) 0.169*** (0.133 to 0.205) 0.038 (−0.000 to 0.076) 0.111** (0.073 to 0.149) 0.159*** (0.122 to 0.197)
 US algorithm 0.026 (0.001 to 0.051) 0.079*** (0.054 to 0.103) 0.116*** (0.091 to 0.141) 0.025 (−0.002 to 0.051) 0.074** (0.048 to 0.100) 0.107*** (0.081 to 0.133)
 VAS 2.9 (−1.1 to 6.9) 11.3*** (7.3 to 15.4) 9.0* (5.0 to 12.9) 1.9 (−2.3 to 6.2) 7.9* (3.7 to 12.2) 11.3*** (7.1 to 15.5)
Physical function (HAQ-DI) −0.17 (−0.26 to −0.08) −0.37*** (−0.46 to −0.28) −0.41*** (−0.49 to −0.32) −0.15 (−0.24 to −0.05) −0.38*** (−0.47 to −0.29) −0.43*** (−0.52 to −0.34)
 % with HAQ-DI <0.5 6% 14%* 14%* 3% 16%*** 16%***
PtGA (VAS) −8.9 (−13.0 to −4.9) −20.4*** (−24.4 to −16.3) −23.0*** (−27.0 to −19.0) −8.8 (−13.1 to −4.6) −20.3*** (−24.6 to −16.1) −24.8*** (−29.0 to −20.6)
Patient's assessment of pain (VAS) −8.8 (−12.9 to −4.7) −17.1*** (−21.2 to −13.0) −22.3*** (−26.3 to −18.2) −8.8 (−13.2 to −4.3) −18.8*** (−23.2 to −14.4) −24.0*** (−28.5 to −19.6)
FACIT-F 5.2 (3.5 to 6.9) 8.3** (6.6 to 9.9) 8.1** (6.5 to 9.8) 5.7 (4.0 to 7.5) 8.1* (6.4 to 9.9) 9.2** (7.5 to 11.0)

Lower scores indicate better outcomes for HAQ-DI, PtGA, patient's assessment of pain. Higher scores indicate better outcomes for EQ-5D.

*p≤0.05, **p≤0.01, ***p≤0.001 versus placebo.

EQ-5D-5L, European Quality of Life-5 Dimensions-5 Levels; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire-Disability Index; PtGA, Patient's Global Assessment of Disease Activity; VAS, visual analogue scale.